Quality of life in low-grade glioma patients receiving temozolomide

Neuro-Oncology

Volumn 11, Issue 1, 2009, Pages 59-68

  Liu, Raymond ^a,d   Solheim, Karla ^b   Polley, Mei Yin ^c   Lamborn, Kathleen R ^c   Page, Margaretta ^c   Fedoroff, Anne ^c   Rabbitt, Jane ^c   Butowski, Nicholas ^c   Prados, Michael ^c   Chang, Susan M ^c  

^a Department of Medicine   (United States)

^b Medical School   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain tumor, chemotherapy; Low grade glioma; Quality of life; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRIVING ABILITY; EMOTION; FEAR; FEMALE; HUMAN; LEFT HEMISPHERE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PATIENT COMPLIANCE; PHYSICAL CAPACITY; QUALITY OF LIFE; RIGHT HEMISPHERE; SEIZURE; SOCIAL ASPECT; SOCIAL INTERACTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WELLBEING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61449249107     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-063     Document Type: Article

References (34)

1. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer. 2006;106:1358-1363.
2. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-2084.
3. Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY. Treatment outcomes and prognostic factors in patients with supratentorial low- grade gliomas. Br J Radiol. 78:230-235.
4. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645.
5. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol. 2006;24:1236-1245.
6. Grier JT, Batchelor T. Low-grade gliomas in adults. Oncologist. 2006;11:681-693.
7. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoas- trocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22:3133-3138.
8. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715-1721.
9. Laack NN, Brown PD, Ivnik RJ, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys. 2005;63:1175-1183.
10. Brown PD, Buckner JC, O'Fallon JR, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol. 2003;21:2519-2524.
11. Torres IJ, Mundt AJ, Sweeney PJ, et al. A longitudinal neuropsycho- logical study of partial brain radiation in adults with brain tumors. Neurology. 2003;60:1113-1118.
12. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34:1902-1909.
13. Gustafsson M, Edvardsson T, Ahlstrom G. The relationship between function, quality of life and coping in patients with low-grade gliomas. Support Care Cancer. 2006;14:1205-1212.
14. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75:1151-1161.
15. Nickolov A, Beumont JL, Victorson D, et al. Validation of functional assessment of cancer therapy: brain (FACT-Br) questionnaire and FACT-Br symptom index (FBrSI) in patients with recurrent high-grade glioma. Paper presented at: Chicago Supportive Oncology Conference; October 6-8, 2005, 2005; Chicago, IL.
16. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
17. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
18. Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007;110:196-202.
19. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
20. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985-990.
21. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose- response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549-556.
22. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267-2276.
23. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361-1368.
24. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys. 2003;55:992-999.
25. Mainio A, Hakko H, Niemela A, Tuurinkoski T, Koivukangas J, Ras- anen P. The effect of brain tumour laterality on anxiety levels among neurosurgical patients. J Neurol Neurosurg Psychiatry. 2003;74:1278-1282.
26. Cummings JL. Neuropsychiatric manifestations of right hemisphere lesions. Brain Lang. 1997;57:22-37.
27. Wasserstein J, Stefanatos GA. The right hemisphere and psycho- pathology. J Am Acad Psychoanal. 2000;28:371-395.
28. Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47:324-333.
29. Heimans JJ, Taphoorn MJ. Impact of brain tumour treatment on quality of life. J Neurol. 2002;249:955-960.
30. Taphoorn MJ, Heimans JJ, Snoek FJ, et al. Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry. 1992;55:372-376.
31. Taphoorn MJ, Schiphorst AK, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol. 1994;36:48-54.
32. Reijneveld JC, Sitskoorn MM, Klein M, Nuyen J, Taphoorn MJ. Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology. 2001;56:618-623.
33. Vitek L, Rosenzweig MQ, Stollings S. Distress in patients with cancer: definition, assessment, and suggested interventions. Clin J Oncol Nurs. 2007;11:413-418.
34. Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol. 2003;63:179-186.